Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

THE WOODLANDS, Texas, Dec. 14, 2010 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis (RA).  LX2931 is an orally-delivered, small molecule drug candidate that inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme important for modulating the immune system by controlling S1P levels in lymphoid tissues. The trial was the first test of this new anti-inflammatory mechanism of action in patients and was designed to obtain safety and tolerability information and signals of efficacy.  

Results from the 12-week, randomized, double-blind, placebo-controlled study in 208 patients with RA demonstrated that all three doses tested, 70 mg, 110 mg, and 150 mg given once per day, were well tolerated over the 12-week treatment period.  Taken together, the data also suggested that patients treated with 150 mg once daily of LX2931 showed an improvement in the primary efficacy endpoint, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12 (60% versus 49% for placebo).  Patients treated with 70 mg or 110 mg once daily did not indicate improvement in the ACR20 at week 12 (44% and 41% response rates, respectively) relative to placebo. Adverse events for all three LX2931 dose groups were predominantly mild-to-moderate, with frequencies similar to the placebo group.

"We believe the preliminary signal of efficacy and the favorable safety profile observed in this trial supports further study
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Medina ... as CEO and member of the Board of Directors ... of medical device development and commercialization experience, including over ... Mr. Engelson previously served as a Partner of the ... President and CEO of two Foundry start-ups. Mr. Engelson ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... , August 29, 2014 ... Seed Oil Market by Extraction type (SFE, Cold ... & Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) ... by MarketsandMarkets, defines and segments the Amaranth Seed ... the market size in terms of value. The ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
... Sept. 21, 2011 Reportlinker.com announces that a ... catalogue: Generic Drugs: The ... http://www.reportlinker.com/p0619264/Generic-Drugs-The-Global-Market-Focus-on-the-Americas.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment ... examination of the strategies employed by companies specializing ...
... SAN DIEGO, Sept. 20, 2011 Orexigen® Therapeutics, Inc. ... a recent meeting with senior officials in FDA,s Office ... detailing OND,s design requirements for a cardiovascular outcomes trial ... Letter (CRL) received in January 2011. Orexigen believes that ...
Cached Medicine Technology:Generic Drugs: The Global Market: Focus on the Americas 2Generic Drugs: The Global Market: Focus on the Americas 3Generic Drugs: The Global Market: Focus on the Americas 4Generic Drugs: The Global Market: Focus on the Americas 5Generic Drugs: The Global Market: Focus on the Americas 6Generic Drugs: The Global Market: Focus on the Americas 7Generic Drugs: The Global Market: Focus on the Americas 8Generic Drugs: The Global Market: Focus on the Americas 9Generic Drugs: The Global Market: Focus on the Americas 10Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 2Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 3Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 4Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 5
(Date:8/29/2014)... According to a CNN article, entitled Medical ... new study found that those states who legalized medical ... decrease in the number of painkiller overdoses seen. By ... and comparing various states with and without legalized medical ... about a 25% decrease in painkiller prescription overdoses in ...
(Date:8/29/2014)... 2014 As reported by the Frederick News Post ... Grad (8/17), a graduate of the Frederick County Drug Treatment ... own experience with the program. The graduate, Korey Shorb, put together ... 1 mile walk. He plans to donate the proceeds of the ... those who helped him. Shorb, who graduated in 2008, admitted that ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe has ... will give patients the convenience of visiting with physicians ... doctors through telemedicine. , Healthpointe doctors are always available ... audio). If necessary, the doctor can even see the ... patient’s condition, he or she can prescribe medications that ...
(Date:8/29/2014)... News) -- Astronauts may be at heightened risk ... immune systems, a new study suggests. That could ... asteroids, the moon and Mars undertaken in the future, ... can be dangerous, NASA researchers say. They found ... of International Space Station crew members remains relatively unchanged ...
(Date:8/29/2014)... 2014 (HealthDay News) -- If you have bunions, taking care ... later, an expert says. A bunion is a bump ... bone or tissue moves out of place and extends beyond ... cause debilitating pain and may require surgery to correct, said ... Center in Freehold, N.J. To prevent bunions, avoid wearing ...
Breaking Medicine News(10 mins):Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 3Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:Take Steps to Control Bunions 2
... Diluted Share, LARGO, Fla., May 28 ... Exchange: UVI), which develops,licenses, manufactures, distributes and markets ... the third quarter and first nine,months of FY2008., ... quarter ended March 31,2008 increased to $1,668,397 compared ...
... 2008 - You went to a wedding yesterday. The service ... dancing all night. But people tell you that you are ... and that you didnt go to a wedding yesterday at ... following neurological damage is known as confabulation. The reasons why ...
... new vegetarian food that boosts the uptake of iron and ... the result of a doctoral dissertation by Charlotte Eklund-Jonsson at ... Sweden. , The food, called tempe, is moreover a whole-grain ... in medicine that whole-grains reduce the risk of cardiovascular diseases, ...
... Hainan, China, May 28 /Xinhua-PRNewswire-FirstCall/ --,China Pharma ... Bulletin,Board: CPHI) which develops, manufactures, and markets ... announced that it has entered,into a Securities ... institutional and accredited investors ("Investors") pursuant to ...
... access to insurance tend to have healthier children , , WEDNESDAY, ... care in America varies widely from state to state, ... likelihood of living long and healthy lives. , That,s the ... a private foundation that seeks to promote better health care ...
... advantage of quick and,easy travel to the beautiful ... Conference: Leadership Development - Finding, Growing & Retaining,Top ... ), sponsored by Best Practices,LLC,s GLOBAL BENCHMARKING ... Fla., Registration ends this week so sign ...
Cached Medicine News:Health News:Unilens Vision Reports Increased Royalty Income 2Health News:Unilens Vision Reports Increased Royalty Income 3Health News:Unilens Vision Reports Increased Royalty Income 4Health News:China Pharma Holdings, Inc. Enters Into Private Placement Agreements to Raise $10 Million 2Health News:China Pharma Holdings, Inc. Enters Into Private Placement Agreements to Raise $10 Million 3Health News:States' Scorecard Finds Big Differences in Kids' Health Care 2Health News:States' Scorecard Finds Big Differences in Kids' Health Care 3Health News:Registration Ends This Week: Fortune 500 Networking & Best Practice Sharing Conference in Florida 2
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: